A Little Below the Belt magazine - Summer 2020

Page 32

Spotlight on bladder and urothelial cancer What is bladder cancer? The bladder is an organ in your pelvis that is part of the urinary system. It works with the kidneys to eliminate the body of waste products from the blood. The bladder has muscular walls that stretch to store urine until it is ready to empty. Urine is liquid waste made by the two kidneys and then carried to the bladder through two tubes called ureters. When you urinate, the muscles in the bladder contract, and urine is forced out of the bladder through a tube called the urethra. Your bladder can hold about 500ml of urine, but you usually feel the need to urinate when it’s holding around 300ml. And just like the urethra, ureters, prostate and renal pelvis, the bladder is lined by a layer of tissue called the urothelium. Bladder cancer develops when abnormal cells in the lining of the bladder grow and divide in an uncontrolled manner. Cancer that begins in the urothelium of the bladder is much more common than cancer that begins in the urothelium of the urethra, ureters, prostate, or renal pelvis.

Types of bladder cancer Bladder cancer takes different forms: • u rothelial carcinoma, formally known as transitional cell carcinoma, is the most common form of bladder cancer (80-90%) and starts in the urothelial cells in the bladder wall’s innermost layer • s quamous cell carcinoma begins in the thin, flat cells that line the bladder • a denocarcinoma is a rare form which starts in mucusproducing cells in the bladder. If you develop bladder cancer in the lining of the bladder it is called superficial bladder cancer. But if the cancer cells spread to the muscle wall of the bladder, or even further to other organs or lymph nodes, it is called invasive bladder cancer.

32 A LITTLE BELOW THE BELT

Bladder cancer remains the only cancer with survival rates that have deteriorated over the past 30 years. Bladder cancer was the 11th most commonly diagnosed cancer in Australia in 2020. In 2020, it is estimated 3098 cases of bladder cancer will be diagnosed in Australia (2389 males and 710 females). This is equivalent to an estimated incidence rate of 9.6 cases per 100,000 persons. In addition, it is estimated there will be 1016 deaths in Australia from bladder cancer but from 2012 – 2016 on average, 54.3% of people diagnosed with bladder cancer survived 5 years after diagnosis.*

Bladder cancer is common in people aged over 60 and is significantly more common in men than in women.


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

Below the Belt #YourWay

14min
pages 64-75

Good2Give

1min
page 62

ANZUP Trials - Kidney

3min
pages 50-51

ANZUP Trials - Testicular

4min
pages 44-45

ANZUP trials - bladder

2min
pages 37-38

Fiona Stanley Hospital urological surgeon puts songwriting talent to the test for Below the Belt campaign

2min
page 34

Spotlight on bladder and urothelian cancer

1min
page 32

ANZUP Trials - Prostate

1min
page 28

Contents

1min
page 4

How can you get involved?

3min
page 61

2020 Below the Belt Research Fund Recipients

6min
pages 59-60

Trials in follow up

11min
pages 56-58

What are the barriers and facilitators to interdisciplinary models of person-centred supportive care in the context of penile cancer? A mixed methods study

4min
pages 54-55

Spotlight on penile cancer

3min
pages 52-53

A pilot study for Kidney Cancer

4min
pages 49-51

Kidney Cancer and Immunotherapy

2min
page 48

Spotlight on kidney cancer

4min
pages 46-47

Testicular Cancer Research Highlights

9min
pages 42-45

Spotlight on testicular cancer

4min
pages 40-41

The role of the Prostate Cancer Subcommittee

11min
pages 26-31

The importance of data to improve patient outcomes with bladder cancer

4min
pages 36-38

Where are we in demonstrating economic value in prostate cancer trials

3min
page 25

Recruitment nearing completion for world first trial for bladder cancer

1min
page 39

Worldwide prostate cancer trial continues to strongly recruit

2min
page 24

Advanced Prostate Cancer Consensus Conference (APCCC): Asia-Pacific (APAC) Satellite Symposium

2min
page 23

ANZUP’s ENZAMET trial is awarded all three of ACTA’s Trial of the Year Awards

4min
pages 21-22

Finding a clinical pathway during a pandemic

4min
pages 14-16

Spotlight on prostate cancer

4min
pages 19-20

Friends of ANZUP

0
page 13

Consumer Advisory Panel (CAP) Update

6min
pages 9-10

Kev’s Crew

3min
pages 11-12

CEO Update

6min
pages 7-8

Meet Associate Professor Arun Azad

3min
pages 17-18

Message from the Chair, Professor Ian Davis

9min
pages 5-6
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.